Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. (October 2019)

• Record Type: Journal Article
• Authors: Wisselink, Daan D.; Braakhuis, Linde L.F.; Gallo, Gaetano; van Grevenstein, Wilhelmina M.U.; van Dieren, Susan; Kok, Niels F.M.; de Reuver, Philip R.; Tanis, Pieter J.; de Hingh, Ignace H.J.T.
• Is Part Of: Critical reviews in oncology/hematology. Volume 142(2019)
• Page Start: 119
• Page End: 129
• Publication Date: 2019-10
• Subjects: Peritoneal metastases -- Colorectal cancer -- Cytoreductive surgery -- HIPEC -- Oxaliplatin -- Mitomycin C -- Morbidity -- Survival; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2019.06.014
• Languages: English
• ISSNs: 1040-8428

Abstract

Highlights: 46 studies on CRS/HIPEC for PMCRC using MMC- or OX-based regimens were included. OX based CRS/HIPEC showed a higher proportion of severe complications. No meaningful comparison could be made regarding DFS and OS. Induction systemic therapy was mostly given in OX studies. The published literature on MMC- or OX-based CRS/HIPEC regimens is very heterogeneous. Abstract: Background: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear. Methods: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter Results: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC. Conclusion: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.